Sign in
4

Changes in Ownership

GeneDx Holdings Corp. Filed Acc 0001689575-25-000015

CHIEF EXECUTIVE OFFICER sold 3,639 shares at $159.28 ($579,620)

  • CHIEF EXECUTIVE OFFICER acquired 6,547 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Stueland Katherine CHIEF EXECUTIVE OFFICER 2025-12-09 Option exercise +6,547 9,983 D
Stueland Katherine CHIEF EXECUTIVE OFFICER 2025-12-09 Sale −3,639 $159.28 $579,620 6,344 D
Derivatives
Stueland Katherine CHIEF EXECUTIVE OFFICER 2025-12-09 Option exercise · Restricted Stock Unit −6,547 26,186 D
Open-market sales · 3,639 sh · avg $159.28 · $579,620
Loading xslF345X05/form4-12112025_091209.xml…